Equity Profile

UTHR

United Therapeutics Corporation

Health CareBiotechnology$22.7B

Jul29Wed

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

United Therapeutics Corporation is a biotechnology company focused on developing innovative therapies for patients with chronic and life-threatening conditions, particularly in the area of pulmonary hypertension. As a player in the health care sector, its advancements can significantly impact patient care and treatment options.

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of profitability and will help gauge the company's financial health this quarter.

N/A

Revenue Growth

Revenue trends provide insight into market demand for United Therapeutics' products and overall business performance.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

UTHR Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

63%

Avg EPS Surprise

+0.12%

Avg Stock Reaction

+0.87%

Last Quarter Recap

In Q1-2026, United Therapeutics reported an EPS of $5.82, which was below the expected $6.73, resulting in a 13.57% surprise. Following the earnings report, the stock rose by 4.29% the next day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Investors are cautious ahead of the upcoming earnings report, especially after the last quarter's EPS miss. The market is looking for signs of recovery in profitability and revenue growth.

Bull Case

If United Therapeutics can exceed EPS expectations and show strong revenue growth, it could signal a turnaround in performance, leading to increased investor confidence.

Bear Case

Conversely, another earnings miss could raise concerns about the company's growth prospects and lead to further stock price declines.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will the EPS exceed the consensus estimate of $6.73?

A positive EPS surprise could indicate improved profitability and boost investor confidence.

What is the revenue growth rate compared to previous quarters?

Understanding revenue trends will help assess market demand and the company's competitive position.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate the potential for a rebound in profitability, given recent product launches and market expansion efforts.

Supporting Evidence

The options market is pricing in a larger move than historical averages, indicating heightened expectations.

United Therapeutics has a history of beating EPS estimates, with a 63% success rate over the last eight quarters.

Key Risk

If the company reports an EPS above $6.73, it could challenge the current cautious sentiment and shift market perceptions.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's earnings report is critical as it follows a disappointing performance last quarter, and investors are keen to see if the company can rebound.

Bull Confirmed If

An EPS of $6.73 or higher would confirm the bull case and indicate strong financial recovery.

Bear Confirmed If

An EPS below $5.50 would confirm the bear case and raise concerns about the company's growth trajectory.

Pre-Earnings Positioning

Options Market

Implied Move

±13.2%

Historical Avg

±6.7%

Pricing rich

The options market is pricing in a significant move of approximately 13.2%, suggesting that traders expect volatility around the earnings announcement.

Options are pricing ±13.2% while UTHR has averaged ±6.7% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.4%

30d HV

25.0%

Calls (5K)P/C Ratio: 1.00Puts (200)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If United Therapeutics beats expectations, history suggests a potential stock increase of around 3.01%, confirming a positive trend.

In-Line / Cautious

If results are in line with expectations, the stock may experience a muted reaction, reflecting ongoing investor caution.

Miss

A miss could lead to a decline of approximately 2.71%, as seen in previous quarters, raising concerns about future growth.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product approvals or pipeline advancements.
2Management's commentary on market demand and competitive landscape.
3Insights into cost management and operational efficiencies.
4Guidance on future revenue expectations and growth strategies.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Jul27

DYNBMO

Dyne Therapeutics, Inc.

PreviewView

Jul27

ARLPBMO

Company Snapshot

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of profitability and will help gauge the company's financial health this quarter.

N/A

Revenue Growth

Revenue trends provide insight into market demand for United Therapeutics' products and overall business performance.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

UTHR Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

63%

Avg EPS Surprise

+0.12%

Avg Stock Reaction

+0.87%

Last Quarter Recap

In Q1-2026, United Therapeutics reported an EPS of $5.82, which was below the expected $6.73, resulting in a 13.57% surprise. Following the earnings report, the stock rose by 4.29% the next day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Investors are cautious ahead of the upcoming earnings report, especially after the last quarter's EPS miss. The market is looking for signs of recovery in profitability and revenue growth.

Bull Case

If United Therapeutics can exceed EPS expectations and show strong revenue growth, it could signal a turnaround in performance, leading to increased investor confidence.

Bear Case

Conversely, another earnings miss could raise concerns about the company's growth prospects and lead to further stock price declines.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will the EPS exceed the consensus estimate of $6.73?

A positive EPS surprise could indicate improved profitability and boost investor confidence.

What is the revenue growth rate compared to previous quarters?

Understanding revenue trends will help assess market demand and the company's competitive position.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate the potential for a rebound in profitability, given recent product launches and market expansion efforts.

Supporting Evidence

The options market is pricing in a larger move than historical averages, indicating heightened expectations.

United Therapeutics has a history of beating EPS estimates, with a 63% success rate over the last eight quarters.

Key Risk

If the company reports an EPS above $6.73, it could challenge the current cautious sentiment and shift market perceptions.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's earnings report is critical as it follows a disappointing performance last quarter, and investors are keen to see if the company can rebound.

Bull Confirmed If

An EPS of $6.73 or higher would confirm the bull case and indicate strong financial recovery.

Bear Confirmed If

An EPS below $5.50 would confirm the bear case and raise concerns about the company's growth trajectory.

Pre-Earnings Positioning

Options Market

Implied Move

±13.2%

Historical Avg

±6.7%

Pricing rich

The options market is pricing in a significant move of approximately 13.2%, suggesting that traders expect volatility around the earnings announcement.

Options are pricing ±13.2% while UTHR has averaged ±6.7% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.4%

30d HV

25.0%

Calls (5K)P/C Ratio: 1.00Puts (200)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If United Therapeutics beats expectations, history suggests a potential stock increase of around 3.01%, confirming a positive trend.

In-Line / Cautious

If results are in line with expectations, the stock may experience a muted reaction, reflecting ongoing investor caution.

Miss

A miss could lead to a decline of approximately 2.71%, as seen in previous quarters, raising concerns about future growth.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product approvals or pipeline advancements.
2Management's commentary on market demand and competitive landscape.
3Insights into cost management and operational efficiencies.
4Guidance on future revenue expectations and growth strategies.